Journal of Infectious Diseases

Journal

Publication Venue For

  • Respiratory Syncytial Virus Antivirals: Problems and Progress..  222:1417-1421. 2020
  • An Integrated Hospital Protocol for Persons With Injection-Related Infections May Increase Medications for Opioid Use Disorder Use but Challenges Remain.  222:S499-S505. 2020
  • Hepatitis C Among High-Risk Alabamians: Disease Burden and Screening Effectiveness.  222:S365-S375. 2020
  • Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium.  222:S175-S198. 2020
  • An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency Virus.  222:S41-S51. 2020
  • Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial.  222:S8-S19. 2020
  • Physical Function Impairment and Frailty in Middle-Aged People Living With Human Immunodeficiency Virus in the REPRIEVE Trial Ancillary Study PREPARE.  222:S52-S62. 2020
  • Pneumococci Can Become Virulent by Acquiring a New Capsule From Oral Streptococci.  222:372-380. 2020
  • Necroptosis inhibition prevents long-term cardiac damage during pneumococcal pneumonia and invasive disease. 2020
  • Immune Activation and Inflammation in People with Human Immunodeficiency Virus: Challenging Targets.  221:1567-1570. 2020
  • Clinical Diagnostic Testing for Human Cytomegalovirus Infections.  221:S74-S85. 2020
  • Cytomegalovirus Genetic Diversity Following Primary Infection.  221:715-720. 2020
  • Advances in the development of therapeutics for cytomegalovirus infections.  221:32-44. 2020
  • Interferon-Induced Transmembrane Protein 3 Genetic Variant rs12252-C Associated with Disease Severity in Coronavirus Disease 2019.  222:34-37. 2020
  • HLA-I Associated Adaptation Dampens CD8 T-Cell Responses in HIV Ad5-Vectored Vaccine Recipients.  220:1620-1628. 2019
  • An Updated Conceptual Model on the Pathogenesis of Bacterial Vaginosis.  220:1399-1405. 2019
  • Timing of Antiretroviral Therapy and Systemic Inflammation in Sub-Saharan Africa: Results from the META Longitudinal Cohort Study.  220:1172-1177. 2019
  • Control of the HIV-1 Load Varies by Viral Subtype in a Large Cohort of African Adults with Incident HIV-1 Infection.  220:432-441. 2019
  • Rapid boosting of HIV-1 neutralizing antibody responses in humans following a prolonged immunologic rest period.  219:1755-1765. 2019
  • Tenofovir gel for prevention of herpes simplex virus type 2 acquisition: Findings from the VOICE trial.  219:1940-1947. 2019
  • Remembering the host in tuberculosis drug development.  219:1518-1524. 2019
  • Blood Viral Load in Symptomatic Congenital Cytomegalovirus Infection.  219:1398-1406. 2019
  • Food Insecurity Is Associated With Inflammation Among Women Living With HIV.  219:429-436. 2019
  • In Silico and Experimental Evaluation of Primer Sets for Species-Level Resolution of the Vaginal Microbiota Using 16S Ribosomal RNA Gene Sequencing.  219:305-314. 2019
  • The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies..  218:1954-1963. 2018
  • Influence of Immune Priming and Egg Adaptation in the Vaccine on Antibody Responses to Circulating A(H1N1)pdm09 Viruses after Influenza Vaccination in Adults.  218:1571-1581. 2018
  • Seroconversion for Cytomegalovirus Infection during Pregnancy and Fetal Infection in a Highly Seropositive Population: "the BraCHS Study".  218:1200-1204. 2018
  • Identification of Key Bacteria Involved in the Induction of Incident Bacterial Vaginosis: A Prospective Study.  218:966-978. 2018
  • Contribution of Breastfeeding to False-Positive Saliva Polymerase Chain Reaction for Newborn Congenital Cytomegalovirus Screening.  217:1612-1615. 2018
  • Kinetics of Serological Responses in Critically Ill Patients Hospitalized with 2009 Pandemic Influenza A(H1N1) Virus Infection in Canada, 2009-2011.  217:1078-1088. 2018
  • Effects of different doses of GEN-003, a therapeutic vaccine for genital herpes simplex virus-2, on viral shedding and lesions: Results of a randomized placebo-controlled trial.  218:1890-1899. 2018
  • Breast milk human cytomegalovirus (CMV) viral load and the establishment of breast milk CMV-pp65-Specific CD8 T Cells in Human CMV infected mothers.  216:1176-1179. 2017
  • Epstein-Barr Virus Type 2 Infects T Cells in Healthy Kenyan Children.  216:670-677. 2017
  • In Memorium: William Ernest Dismukes 1939-2017. 2017
  • New Horizons in Mycoplasma genitalium Treatment.  216:S412-S419. 2017
  • Pathological Role of Anti-CD4 Antibodies in HIV-Infected Immunologic Nonresponders Receiving Virus-Suppressive Antiretroviral Therapy.  216:82-91. 2017
  • Lower Levels of Cervicovaginal Tryptophan Are Associated with Natural Clearance of Chlamydia in Women.  215:1888-1892. 2017
  • Clinical trial of the anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy.  215:1725-1733. 2017
  • Immunoglobulin-based investigation of spontaneous resolution of chlamydia trachomatis infection.  215:1653-1656. 2017
  • Therapeutic vaccine for Genital herpes simplex virus-2 infection: Findings from a randomized trial.  215:856-864. 2017
  • TURQUOISE-I part 1b: Ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin for hepatitis C virus infection in HIV-1 coinfected patients on darunavir.  215:599-605. 2017
  • Association of macrophage inflammation biomarkers with progression of subclinical carotid artery atherosclerosis in HIV-infected women and men.  215:1352-1361. 2017
  • Cross-reactive antibody responses to novel h5nx influenza viruses following homologous and heterologous prime-boost vaccination with a prepandemic stockpiled a(h5n1) vaccine in humans.  216:S555-S559. 2017
  • Diversity in the US Infectious Diseases Workforce: Challenges for Women and Underrepresented Minorities.  216:S606-S610. 2017
  • Effect of priming with seasonal influenza a(h3n2) virus on the prevalence of cross-reactive hemagglutination-inhibition antibodies to swine-origin a(h3n2) variants.  216:S539-S547. 2017
  • Mild respiratory illness among young children caused by highly pathogenic avian influenza a (h5n1) virus infection in Dhaka, Bangladesh, 2011.  216:S520-S528. 2017
  • Pathogenesis of Non-Zika Congenital Viral Infections.  216:S912-S918. 2017
  • Sunday in the Park with Infectious Disease: Workforce Mismatch in a Colorful Universe of Possibilities.  216:S581-S587. 2017
  • Intra-amniotic ureaplasma parvum-induced maternal and fetal inflammation and immune responses in rhesus macaques.  214:1597-1604. 2016
  • Seasonal influenza vaccination of children induces humoral and cell-mediated immunity beyond the current season: Cross-reactivity with past and future strains.  214:1477-1486. 2016
  • Influenza vaccination and antiviral therapy in pregnant women.  214:505-506. 2016
  • More Easily Cultivated Than Identified: Classical Isolation with Molecular Identification of Vaginal Bacteria.  214:S21-S28. 2016
  • Pathogenesis of Bacterial Vaginosis: Discussion of Current Hypotheses.  214:S1-S5. 2016
  • The Vaginal Microbiome: Current Understanding and Future Directions.  214:S36-S41. 2016
  • Uropathogenic Escherichia coli engages CD14-dependent signaling to enable bladder-macrophage-dependent control of acute urinary tract infection.  213:659-668. 2016
  • Vaccination with heterologous HIV-1 envelope sequences and heterologous adenovirus vectors increases T-cell responses to conserved regions: HVTN 083.  213:541-550. 2016
  • Incidence and predictors of abnormal anal cytology findings among HIV-infected adults receiving contemporary antiretroviral therapy.  213:351-360. 2016
  • Pharmacological measures of treatment adherence and risk of HIV infection in the VOICE study.  213:335-342. 2016
  • Whole-exome sequencing reveals mutations in genes linked to hemophagocytic lymphohistiocytosis and macrophage activation syndrome in fatal cases of H1N1 influenza.  213:1180-1188. 2016
  • Breast Milk as a Potential Source of Epstein-Barr Virus Transmission Among Infants Living in a Malaria-Endemic Region of Kenya.  212:1735-1742. 2015
  • A murine viral outgrowth assay to detect residual HIV type 1 in patients with undetectable viral loads.  212:1387-1396. 2015
  • The Role of Conserved N-Linked Glycans on Ebola Virus Glycoprotein 2.  212:S204-S209. 2015
  • Challenges and opportunities in developing respiratory syncytial virus therapeutics.  211:S1-S20. 2015
  • A newly emerged swine-origin influenza a(H3N2) variant dampens host antiviral immunity but induces potent inflammasome activation.  212:1923-1929. 2015
  • Antibody to influenza virus neuraminidase: An independent correlate of protection.  212:1191-1199. 2015
  • Oral and vaginal tenofovir for genital herpes simplex virus type 2 shedding in immunocompetent women: A double-blind, randomized, cross-over trial.  212:1949-1956. 2015
  • Rapid and profound shifts in the vaginal microbiota following antibiotic treatment for bacterial vaginosis.  212:793-802. 2015
  • Safer conception strategies for HIV-serodiscordant couples: How safe is safe enough?.  212:1525-1528. 2015
  • Role of Gardnerella vaginalis in the pathogenesis of bacterial vaginosis: A conceptual model.  210:338-343. 2014
  • Basophil expansion protects against invasive pneumococcal disease in mice.  210:14-24. 2014
  • Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia ankara vaccines expressing HIV-1 virus-like particles.  210:99-110. 2014
  • The scarlet H.  209:315-317. 2014
  • Aging promotes b-1b cell responses to native, but not protein-conjugated, pneumococcal polysaccharides: Implications for vaccine protection in older adults.  209:87-97. 2014
  • Detection of congenital cytomegalovirus infection by real-time polymerase chain reaction analysis of saliva or urine specimens.  210:1415-1418. 2014
  • HIV-1 infection of macrophages dysregulates innate immune responses to mycobacterium tuberculosis by inhibition of interleukin-10.  209:1055-1065. 2014
  • Low invasiveness of pneumococcal serotype 11A is linked to ficolin-2 recognition of O-acetylated capsule epitopes and lectin complement pathway activation.  210:1155-1165. 2014
  • Organ pathology in the absence of bacteria?.  209:971. 2014
  • Reply to hickey and forney.  210:1683-1684. 2014
  • Selected vaginal bacteria and risk of preterm birth: An ecological perspective.  209:1087-1094. 2014
  • Serum antibody response to matrix protein 2 following natural infection with 2009 pandemic influenza A(H1N1) virus in humans.  209:986-994. 2014
  • Transplacental transfer of azithromycin and its use for eradicating intra-amniotic ureaplasma infection in a primate model.  209:898-904. 2014
  • Changes in measles serostatus among HIV-infected zambian children initiating antiretroviral therapy before and after the 2010 measles outbreak and supplemental immunization activities.  208:1747-1755. 2013
  • Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA Randomized Trial): An unexpected observation.  208:1391-1396. 2013
  • Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals.  208:1240-1249. 2013
  • Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248.  208:884-891. 2013
  • Heterozygosity for the F508del mutation in the cystic fibrosis transmembrane conductance regulator anion channel attenuates influenza severity.  208:780-789. 2013
  • Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission.  208:662-671. 2013
  • Spontaneous resolution of genital chlamydia trachomatis infection in women and protection from reinfection.  207:1850-1856. 2013
  • Inducible nitric oxide contributes to viral pathogenesis following highly pathogenic influenza virus infection in mice.  207:1576-1584. 2013
  • Vaginal biofilms and bacterial vaginosis: Of mice and women.  207:1481-1483. 2013
  • Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenza.  207:709-720. 2013
  • Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia ankara as a smallpox vaccine in HIV-infected subjects.  207:749-758. 2013
  • Protein energy malnutrition decreases immunity and increases susceptibility to influenza infection in mice.  207:501-510. 2013
  • Immunoglobulin-specific responses to chlamydia elementary bodies in individuals with and at risk for genital chlamydial infection.  206:1836-1843. 2012
  • Mucosal escherichia coli bactericidal activity and immune mediators are associated with HIV-1 seroconversion in women participating in the HPTN 035 trial.  206:1931-1935. 2012
  • Oseltamivir dosing in premature infants.  206:847-850. 2012
  • Protecting adults from influenza: Tis the season to learn from the pandemic.  206:803-805. 2012
  • Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.  206:431-441. 2012
  • HLA-B signal peptide polymorphism influences the rate of HIV-1 acquisition but not viral load.  205:1797-1805. 2012
  • Extravaginal reservoirs of vaginal bacteria as risk factors for incident bacterial vaginosis.  205:1580-1588. 2012
  • Tuberculosis and HIV control in sub-saharan african prisons: "thinking outside the prison cell".  205. 2012
  • Sometimes, more is better.  205:697-699. 2012
  • Local innate immune responses and influenza virus transmission and virulence in ferrets.  205:474-485. 2012
  • Reply to Ganesan et al.  205:518-519. 2012
  • Use of a human influenza challenge model to assess person-to-person transmission: Proof-of-concept study.  205:35-43. 2012
  • A pre-pandemic outbreak of triple-reassortant swine influenza virus infection among university students, South Dakota, 2008.  204:1165-1171. 2011
  • Mixed infection and strain diversity in congenital cytomegalovirus infection.  204:1003-1007. 2011
  • Expression of innate and adaptive immune mediators in human corneal tissue infected with Aspergillus or fusarium..  204:942-950. 2011
  • Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: Implications for tuberculosis screening.  204:893-901. 2011
  • Establishing and sustaining a healthy vaginal environment: Analysis of data from a randomized trial of periodic presumptive treatment for vaginal infections.  204:323-326. 2011
  • Increasing clarity on bone loss associated with antiretroviral initiation.  203:1705-1707. 2011
  • Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women.  203:1534-1541. 2011
  • Increases in human papillomavirus detection during early HIV infection among women in Zimbabwe.  203:1182-1191. 2011
  • Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.  203:610-619. 2011
  • Divergent mechanisms for passive pneumococcal resistance to β-Lactam antibiotics in the presence of Haemophilus influenzae.  203:549-555. 2011
  • Impact of a functional KIR2DS4 allele on heterosexual HIV-1 transmission among discordant Zambian couples.  203:487-495. 2011
  • Control of varicella disease, version 2.0.  203:297-298. 2011
  • Infection with highly pathogenic H7 influenza viruses results in an attenuated proinflammatory cytokine and chemokine response early after infection.  203:40-48. 2011
  • Bacterial vaginosis assessed by Gram stain and diminished colonization resistance to incident gonococcal, chlamydial, and trichomonal genital infection.  202:1907-1915. 2010
  • Cytomegalovirus viruria and DNAemia in healthy seropositive women.  202:1800-1803. 2010
  • Factors associated with prevalent abnormal anal cytology in a large cohort of HIV-infected adults in the United States.  202:1567-1576. 2010
  • Mice lacking both TNF and IL-1 receptors exhibit reduced lung inflammation and delay in onset of death following infection with a highly virulent H5N1 virus.  202:1161-1170. 2010
  • Coinfection with Haemophilus influenzae promotes pneumococcal biofilm formation during experimental otitis media and impedes the progression of pneumococcal disease.  202:1068-1075. 2010
  • Reply to Tarchini.  202:979. 2010
  • Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: An AIDS clinical trials group study.  202:717-722. 2010
  • Oseltamivir dosing for influenza infection in premature neonates.  202:563-566. 2010
  • A new pneumococcal serotype, 11E, has a variably inactivated wcjE Gene.  202:29-38. 2010
  • Duration of untreated, uncomplicated chlamydia trachomatis genital infection and factors associated with chlamydia resolution: A review of human studies.  201. 2010
  • A Phase III equivalence trial of azithromycin versus benzathine penicillin for treatment of early syphilis.  201:1729-1735. 2010
  • Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.  201:1481-1487. 2010
  • Of ferrets and humans: Influenza pathogenesis.  201:976-977. 2010
  • Group B Streptococcus (GBS) urinary tract infection involves binding of GBS to bladder uroepithelium and potent but GBS-specific induction of interleukin 1α.  201:866-870. 2010
  • Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.  201:803-813. 2010
  • An evolving understanding of genital herpes pathogenesis: Is it time for our approach to therapy to change as well?.  201:486-487. 2010
  • Cytomegalovirus reinfections in healthy seroimmune women.  201:386-389. 2010
  • Repeated Chlamydia trachomatis genital infections in adolescent women.  201:42-51. 2010
  • A live attenuated H1N1 M1 mutant provides broad cross-protection against influenza A viruses, including highly pathogenic A/Vetnam/1203/2004, in Mice.  200:1874-1883. 2009
  • Role played by psrP-secY2A2 (accessory region 34) in the invasive disease potential of streptococcus pneumoniae.  200:1180-1181. 2009
  • Age-associated inflammation and Toll-like receptor dysfunction prime the lungs for pneumococcal pneumonia.  200:546-554. 2009
  • Risk factors associated with subclinical human infection with avian influenza a (H5N1) virus-cambodia, 2006.  199:1744-1752. 2009
  • A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.  199:1638-1647. 2009
  • Reply to Zhang.  199:1250-1251. 2009
  • Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African Americans.  199:872-880. 2009
  • Streptococcus pneumoniae forms surface-attached communities in the middle ear of experimentally infected chinchillas.  199:786-794. 2009
  • Distribution of genital Lactobacillus strains shared by female sex partners.  199:680-683. 2009
  • Increase in the prevalence of the newly discovered pneumococcal serotype 6C in the nasopharynx after introduction of pneumococcal conjugate vaccine.  199:320-325. 2009
  • Differential effects of pneumococcal vaccines against serotypes 6A and 6C.  198:1818-1822. 2008
  • Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.  198:1345-1352. 2008
  • Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia.  198:1019-1027. 2008
  • Antibodies against PsrP, a novel Streptococcus pneumoniae adhesin, block adhesion and protect mice against pneumococcal challenge.  198:375-383. 2008
  • A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses.  197:1185-1188. 2008
  • Efavirenz-Based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts.  197:1006-1010. 2008
  • Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease.  197:836-845. 2008
  • Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects.  197:867-870. 2008
  • Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women.  197:548-554. 2008
  • Lack of evidence of avian-to-human transmission of avian influenza A (H5N1) virus among poultry workers, Kano, Nigeria, 2006.  196:1685-1691. 2007
  • Antibodies to pneumococcal surface protein A families 1 and 2 in serum and saliva of children and the risk of pneumococcal acute otitis media.  196:1528-1536. 2007
  • DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza h5N1 virus infection.  196:1493-1499. 2007
  • Selective testing criteria for gonorrhea among young women screened for chlamydial infection: Contribution of race and geographic prevalence.  196:731-737. 2007
  • HLA class I-restricted T cell epitopes of the kinetoplastid membrane protein-11 presented by Leishmania donovani-infected human macrophages.  195:1373-1380. 2007
  • Correlates of sexually transmitted infections in young women [1].  195:303. 2007
  • Functionally competent antigen-specific Cd127hi memory CD8 + T cells are preserved only in HIV-infected individuals receiving early treatment.  195:108-117. 2007
  • Haplotypes of IL6 and IL10 and susceptibility to human T lymphotropic virus type I infection among children.  194:1565-1569. 2006
  • Prevalence of primary HIV-1 drug resistance among recently infected adolescents: A Multicenter Adolescent Medicine Trials Network for HIV/AIDS Interventions Study.  194:1505-1509. 2006
  • Reply to Forney et al. [4].  194:1469-1470. 2006
  • Reply to Lawn and Wood [2].  194:1468. 2006
  • Lessons learned from reconstructing the 1918 influenza pandemic.  194. 2006
  • Prevention and treatment of influenza in high-risk groups: Children, pregnant women, immunocompromised hosts, and nursing home residents.  194. 2006
  • Seasonal and pandemic influenza preparedness: A global threat.  194. 2006
  • Seasonal and pandemic influenza: Recommendations for preparedness in the United States.  194. 2006
  • Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: The results of AIDS Clinical Trials Group 5068.  194:623-632. 2006
  • Time to translate new knowledge into practice: A call for a national genital herpes control program.  194:6-7. 2006
  • A persistent(ly) enigmatic ecological mystery: Bacterial vaginosis.  193:1475-1477. 2006
  • Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy.  193:1437-1440. 2006
  • Host immunogenetics and control of human herpesvirus-8 infection.  193:1054-1062. 2006
  • The spectrum of genital herpes simplex virus infection in men attending a sexually transmitted disease clinic.  193:905-911. 2006
  • Risk factors for cervicitis among women with bacterial vaginosis.  193:617-624. 2006
  • Local and systemic cytokine levels in relation to changes in vaginal flora.  193:556-562. 2006
  • Behavioral risk exposure and host genetics of susceptibility to HIV-1 infection.  193:16-26. 2006
  • Prevalence, incidence, natural history, and response to treatment of Trichomonas vaginalis infection among adolescent women.  192:2039-2044. 2005
  • Association between human leukocyte antigen class II alleles and genotype of Borrelia burgdorferi in patients with early Lyme disease.  192:2020-2026. 2005
  • Association between genital tract cytomegalovirus infection and bacterial vaginosis.  192:1727-1730. 2005
  • Molecular epidemiology of foodborne hepatitis A outbreaks in the United States, 2003.  192:1323-1330. 2005
  • A case-control study to examine HLA haplotype associations in patients with posttreatment chronic lyme disease.  192:1010-1013. 2005
  • High-dose recombinant canarypox vaccine expressing HIV-1 protein, in seronegative human subjects.  192:1249-1259. 2005
  • Treatment of intestinal helminths does not reduce plasma concentrations of HIV-1 RNA in coinfected Zambian adults.  192:1277-1283. 2005
  • Virulence in mice of pneumococcal clonal types with known invasive disease potential in humans.  192:791-800. 2005
  • Changing dynamics of varicella-zoster virus infections in the 21st century: The impact of vaccination.  191:1999-2001. 2005
  • Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A potential priming strategy.  191:1210-1215. 2005
  • Human leukocyte antigen and cytokine gene variants as predictors of recurrent Chlamydia trachomatis infection in high-risk adolescents.  191:1084-1092. 2005
  • Detection of cytomegalovirus (CMV) DNA by polymerase chain reaction is associated with hearing loss in newborns with symptomatic congenital CMV infection involving the central nervous system.  191:227-233. 2005
  • Influence of host genetic variation on susceptibility to HIV type 1 infection.  191. 2005
  • Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA Loads.  190:1970-1978. 2004
  • Epidemiological and genetic correlates of incident Chlamydia trachomatis infection in North American adolescents.  190:1723-1729. 2004
  • Tissue-specific contributions of pneumococcal virulence factors to pathogenesis.  190:1661-1669. 2004
  • Commentary: Ch'ien LT, Cannon NJ, Charamella LJ, et al. Effect of adenine arabinoside on severe herpesvirus hominis infections in man: Preliminary report. J Infect Dis 1973; 128:658-63.  190:1360-1367. 2004
  • Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen.  190:928-934. 2004
  • Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis) - Resistant mutants.  190:975-978. 2004
  • Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects.  190:886-893. 2004
  • Recombinant interferon-γ1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis.  189:2185-2191. 2004
  • Activation of porcine cytomegalovirus, but not porcine lymphotropic herpesvirus, in pig-to-baboon xenotransplantation.  189:1628-1633. 2004
  • HLA-DRB1 and -DQB1 alleles and haplotypes in Zambian couples and their associations with heterosexual transmission of HIV type 1.  189:1696-1704. 2004
  • Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.  189:1221-1231. 2004
  • Hepatitis C virus quasi-species dynamics predict progression of fibrosis after liver transplantation.  189:2037-2046. 2004
  • Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials group study 359.  189:1176-1184. 2004
  • Effect of adenine arabinoside on severe Herpesvirus hominis infections in man. 1973..  190:1362-1367. 2004
  • Influence of human leukocyte antigen-B22 alleles on the course of human immunodeficiency virus type 1 infection in 3 cohorts of white men.  188:856-863. 2003
  • A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.  188:625-634. 2003
  • High rates of Trichomonas vaginalis among men attending a sexually transmitted diseases clinic: Implications for screening and urethritis management.  188:465-468. 2003
  • Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae.  188:339-348. 2003
  • Long‐Cycle Structured Intermittent versus Continuous Highly Active Antiretroviral Therapy for the Treatment of Chronic Infection with Human Immunodeficiency Virus: Effects on Drug Toxicity and on Immunologic and Virologic Parameters.  188:388-396. 2003
  • Heritability analysis of cytokines as intermediate phenotypes of tuberculosis.  187:1679-1685. 2003
  • Association of CTLA4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection.  187:1264-1271. 2003
  • Immunogenic protein contaminants in pneumococcal vaccines.  187:1019-1023. 2003
  • Limited asymptomatic carriage of Pneumocystis jiroveci in human immunodeficiency virus-infected patients.  187:901-908. 2003
  • Cytomegalovirus production by infected astrocytes correlates with transforming growth factor-β release.  187:534-541. 2003
  • Antigen burden is a major determinant of human immunodeficiency virus-specific CD8+ T cell maturation state: Potential implications for therapeutic immunization.  187:364-374. 2003
  • A nontoxic chimeric enterotoxin adjuvant induces protective immunity in both mucosal and systemic compartments with reduced ige antibodies.  186:1261-1269. 2002
  • Durability of response to treatment among antiretroviral-experienced subjects: 48-Week results from AIDS Clinical Trials Group Protocol 359.  186:626-633. 2002
  • Role of bacteriophage MAV1 as a mycoplasmal virulence factor for the development of arthritis in mice and rats.  186:432-435. 2002
  • The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (aids clinical trials group study 850).  186:198-204. 2002
  • Evaluation of initial CD4+ T cell counts in individuals with newly diagnosed human immunodeficiency virus infection, by sex and race, in urban settings..  185:1818-1821. 2002
  • Characterization of vaginal flora and bacterial vaginosis in women who have sex with women.  185:1307-1313. 2002
  • Human cytomegalovirus enhances chemokine production by lipopolysaccharide-stimulated lamina propria macrophages.  185:584-590. 2002
  • Correlates of nontransmission in US women at high risk of human immunodeficiency virus type 1 infection through sexual exposure.  185:428-438. 2002
  • Human cytomegalovirus primes lamina propria macrophages for enhanced LPS-stimulated chemokine production.  185:584-90. 2002
  • Pilot Study of the Effects of Intermittent Interleukin‐2 on Human Immunodeficiency Virus (HIV)–Specific Immune Responses in Patients Treated during Recently Acquired HIV Infection.  185:61-8. 2002
  • Risk of influenza A (H5N1) infection among poultry workers, Hong Kong, 1997-1998.  185:1005-1010. 2002
  • Growth inhibition of Candida albicans by human vaginal epithelial cells.  184:1489-1493. 2001
  • Quantitative culture of Chlamydia trachomatis: Relationship of inclusion-forming units produced in culture to clinical manifestations and acute inflammation in urogenital disease.  184:1350-1354. 2001
  • Level of maternal antibody required to protect neonates against early-onset disease caused by group B streptococcus type Ia: A multicenter, seroepidemiology study.  184:1022-1028. 2001
  • Modification of maternal and congenital cytomegalovirus infection by anti-glycoprotein b antibody transfer in guinea pigs..  183:1547-1553. 2001
  • Polar production of interleukin-8 by mesothelial cells promotes the transmesothelial migration of neutrophils: Role of intercellular adhesion molecule-1.  183:1638-1645. 2001
  • Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant.  183:1688-1693. 2001
  • Clones of Streptococcus pneumoniae isolated from nasopharyngeal carriage and invasive disease in young children in central Tennessee.  183:1501-1507. 2001
  • Immunologic profile of human immunodeficiency virus-infected patients during viral remission and relapse on antiretroviral therapy.  183:1522-1525. 2001
  • Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 env, gag, and pro in combination with RGP120.  183:563-570. 2001
  • Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes.  183:368-376. 2001
  • Onchocerciasis in a nonendemic population: Clinical and immunologic assessment before treatment and at the time of presumed cure.  183:512-516. 2001
  • Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infection.  183:401-408. 2001
  • Epidemiology and clinical manifestations of unique Chlamydia trachomatis isolates that occupy nonfusogenic inclusions.  184:879-884. 2001
  • Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS clinical trials group protocol 373.  183:715-721. 2001
  • Enterotoxin adjuvants have direct effects on T cells and antigen- presenting cells that result in either interleukin-4-dependent or - independent immune responses.  182:180-190. 2000
  • Induction of acute pleural inflammation by Staphylococcus aureus. I. Cd4+ T cells play a critical role in experimental empyema.  181:1693-1699. 2000
  • A foodborne outbreak of gastroenteritis associated with Norwalk-like viruses: First molecular traceback to deli sandwiches contaminated during preparation.  181:1467-1470. 2000
  • Inflammatory cytokine mRNA expression during early and persistent Helicobacter pylori infection in nonhuman primates.  181:783-786. 2000
  • Risk of influenza A (H5N1) infection among health care workers exposed to patients with influenza A (H5N1), Hong Kong.  181:344-348. 2000
  • Growth inhibition of Candida by human oral epithelia cells.  182:1479-1485. 2000
  • Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA.  182:1694-1701. 2000
  • Lamina propria lymphocytes, not macrophages, express CCR5 and CXCR4 and are the likely target cell for human immunodeficiency virus type 1 in the intestinal mucosa.  182:785-791. 2000
  • Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media.  182:1146-1152. 2000
  • Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts.  180:1763-1770. 1999
  • Evaluation of distinct blood lymphocyte populations in human immunodeficiency virus type 1-infected subjects in the absence or presence of effective therapy.  180:1851-1862. 1999
  • A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant.  180:970-975. 1999
  • Case-control study of risk factors for avian influenza A (H5N1) disease, Hong Kong, 1997.  180:505-508. 1999
  • Consistent associations of HLA class I and II and transporter gene products with progression of human immunodeficiency virus type 1 infection in homosexual men.  180:299-309. 1999
  • Human interleukin-12 enhances interferon-γ-producing influenza-specific memory CD8+ cytotoxic T lymphocytes.  180:1477-1486. 1999
  • Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants.  180:1569-1576. 1999
  • Mycobacterium-induced transmesothelial migration of monocytes into pleural space: Role of intercellular adhesion molecule-1 in tuberculous pleurisy.  180:1616-1623. 1999
  • Involvement of matrix metalloproteinases in human immunodeficiency virus type 1-induced replication by clinical Mycobacterium avium isolates..  180:1142-1152. 1999
  • Asymptomatic primary cytomegalovirus infection: Virologic and immunologic features.  180:702-707. 1999
  • Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy.  180:847-849. 1999
  • Differential susceptibility of two species of macaques to experimental vaginal candidiasis.  180:802-810. 1999
  • Nasal immunization induces Haemophilus influenzae-specific Th1 and Th2 responses with mucosal IgA and systemic IgG antibodies for protective immunity.  180:122-132. 1999
  • Mucosal Th1- versus Th2-type responses for antibody- or cell-mediated immunity to simian immunodeficiency virus in rhesus macaques.  179. 1999
  • Mucosal events in the pathogenesis of human immunodeficiency virus type 1 infection.  179. 1999
  • Mucosal immune system of the human genital tract.  179. 1999
  • Cryptococcosis: Population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons.  179:449-454. 1999
  • Molecular characterization of a globally distributed lineage of serotype 12F Streptococcus pneumoniae causing invasive disease.  179:414-422. 1999
  • Herpes zoster: Risk categories for persistent pain.  179:9-15. 1999
  • HIV-1 Infection, mucosal immunity and pathogenesis: Comments and conference summary.  179:397-400. 1999
  • Genital human papillomavirus infection in women who have sex with women.  178:1604-1609. 1998
  • Identification of T cells that respond to serovar-specific regions of the Chlamydia trachomatis major outer membrane protein in persons with serovar E infection.  178:1713-1718. 1998
  • Sequence polymorphisms in the Pneumocystis carinii cytochrome b gene and their association with atovaquone prophylaxis failure.  178:1767-1775. 1998
  • Mycobacterium-mediated chemokine expression in pleural mesothelial cells: role of C-C chemokines in tuberculous pleurisy..  178:1450-1456. 1998
  • Capsular polysaccharide types of group B streptococcal isolates from neonates with early-onset systemic infection.  177:790-792. 1998
  • Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: A meta-analysis of randomized individual patient data.  178:349-359. 1998
  • Cytokine and antibody responses in women infected with Neisseria gonorrhoeae: Effects of concomitant infections.  178:742-751. 1998
  • Erratum: Retraction: A rabbit model for human cytomegalovirus-induced chorioretinal disease (The Journal of Infectious Diseases (1998) 177 (1778)).  178:601. 1998
  • Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1(MN) gp120, HIV-1(SF2) recombinant gp120, or both vaccines in seronegative adults.  177:1230-1246. 1998
  • Induction of Th2 cytokine expression for p27-specific IgA B cell responses after targeted lymph node immunization with simian immunodeficiency virus antigens in rhesus macaques.  177:26-33. 1998
  • Recombinant helicobactev pylori urease activates primary mucosal macrophages.  178:1516-1520. 1998
  • Retraction: A rabbit model for human cytomeglovirus--induced chorioretinal disease (J Infect Dis 1993;168:336-44)..  177:1778. 1998
  • The identification of risk factors associated with persistent pain following herpes zoster.  178. 1998
  • Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy.  177:40-47. 1998
  • Use of statistics and scientific inference: Odds ratios, likelihood ratio, and receiving operating characteristic curves [2] (multiple letters).  178:921-923. 1998
  • Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group..  175:1080-1086. 1997
  • A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis.  176:227-232. 1997
  • Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine.  175:352-363. 1997
  • Age-related decline in murine macrophage production of nitric oxide.  175:1004-1007. 1997
  • Alterations to the cell wall of Histoplasma capsulatum yeasts during infection of macrophases or epithelial cells.  175:1538-1544. 1997
  • Antimicrobial resistance in Neisseria genorrhoeae in the United States, 1988-1994: The emergence of decreased susceptibility to the fluoroquinolones.  175:1396-1403. 1997
  • Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: Results of a phase II study.  175:1080-1086. 1997
  • High incidence of Kaposi's sarcoma-associated herpesvirus and Epstein- Barr virus in tumor lesions and peripheral blood mononuclear cells from patients with Kaposi's sarcoma in Uganda.  175:947-950. 1997
  • Identification of cross-reactive antibodies with low opsonophagocytic activity for Streptococcus pneumoniae.  176:698-703. 1997
  • Intranasal immunization of mice with PspA (Pneumococcal surface protein A) can prevent lntranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae.  175:839-846. 1997
  • A modified Farr assay is more specific than ELISA for measuring antibodies to Streptococcus pneumoniae capsular polysaccharides.  173:113-118. 1996
  • Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease.  174:1162-1167. 1996
  • DNA polymorphisms and variant penicillin-binding proteins as evidence that relatively penicillin-resistant pneumococci in Western Canada are clonally related.  174:884-888. 1996
  • Disposition of zidovudine in obese pregnant women with human immunodeficiency virus type 1 infection [4].  174:673. 1996
  • Effects of influenza A nucleoprotein on polymorphonuclear neutrophil function.  173:279-284. 1996
  • Genetic diversity at the internal transcribed spacer regions of the rRNA operon among isolates of Pneumocystis carinii from AIDS patients with recurrent pneumonia.  174:141-156. 1996
  • Immunoregulation in onchocerciasis: Persons with ocular inflammatory disease produce a Th2-like response to Onchocerca volvulus antigen.  174:380-386. 1996
  • Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin.  173:627-635. 1996
  • Pneumococcal vaccine response in human immunodeficiency virus-infected patients.  173:777-778. 1996
  • Synthesis of tumor necrosis factor-α mRNA in bronchoalveolar lavage cells from human immunodeficiency virus-infected persons with Pneumocystis carinii pneumonia.  174:654-659. 1996
  • The presence or absence of active infection, not clinical status, is most closely associated with cytokine responses in lymphatic filariasis.  173:1453-1459. 1996
  • The repertoire of human antibodies to the carbohydrate capsule of Streptococcus pneumoniae 6B.  174:75-82. 1996
  • Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice.  173:380-386. 1996
  • Diagnosis of herpes simplex encephalitis: application of polymerase chain reaction to cerebrospinal fluid from brain-biopsied patients and correlation with disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group..  171:857-863. 1995
  • A randomized, double-blind, placebo-controlled trial of systemically administered interferon-α, -β, or -γ in combination with cryotherapy for the treatment of condyloma acuminatum.  171:1081-1089. 1995
  • Abnormal lymphatic function in presymptomatic bancroftian filariasis.  171:997-1001. 1995
  • Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection.  171:1115-1121. 1995
  • Detection of herpesvirus dna by nested polymerase chain reaction in cerebrospinal fluid of human immunodeficiency virus-infected persons with neurologic disease: A prospective evaluation.  172:1087-1090. 1995
  • Diagnosis of herpes simplex encephalitis: Application of polymerase chain reaction to cerebrospinal fluid from brain-biopsied patients and correlation with disease.  171:857-863. 1995
  • Modulation of human immunodeficiency virus type 1 infection of human monocytes by iga.  172:855-858. 1995
  • Reduced congenital cytomegalovirus (CMV) infection after maternal immunization with a guinea pig CMV glycoprotein before gestational primary cmv infection in the guinea pig model.  172:1212-1220. 1995
  • Virus-specific antibody responses to human cytomegalovirus (hcmv) in human immunodeficiency virus type 1-infected persons with hcmv retinitis.  171:182-185. 1995
  • Association of hepatitis c virus infection with false-positive tests for syphilis.  170:1579-1581. 1994
  • Characterization of mucosal antibodies in persons with AIDS.  170:299-307. 1994
  • Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases.  169:990-995. 1994
  • Intestinal mucosal immunoglobulins during human immunodeficiency virus type 1 infection.  170:299-307. 1994
  • Lymphoscintigraphic analysis of lymphatic abnormalities in symptomatic and asymptomatic human filariasis.  170:927-933. 1994
  • Truly infection-free persons are rare in areas hyperendemic for african onchocerciasis.  170:1054-1055. 1994
  • A Rabbit Model for Human Cytomegalovirus-Induced Chorioretinal Disease.  168:336-344. 1993
  • Antibodies Induced by a Primary Cytomegalovirus Infection React with Human Herpesvirus 6 Proteins.  168:1119-1126. 1993
  • Cytoadherence of plasmodium falciparum-infected erythrocytes to microvascular endothelium is regulatable by cytokines and phorbol ester.  167:698-703. 1993
  • Esophageal disease in AIDS is associated with pathologic processes rather than mucosal human immunodeficiency virus type 1.  167:547-552. 1993
  • Oral immunization with influenza virus in biodegradable microspheres.  167:84-90. 1993
  • Parvovirus Bl9-specific DNA in bone marrow from B19 arthropathy patients: Evidence for B19 virus persistence.  167:744-748. 1993
  • Penile Intraepithelial Neoplasia: Clinical Presentation and an Analysis of the Physical State of Human Papillomavirus DNA.  168:38-46. 1993
  • Transmission of Chlamydia trachomatis among Sex Partners Assessed by Polymerase Chain Reaction.  168:488-492. 1993
  • Virus-specific antibody responses in mothers and their newborn infants with asymptomatic congenital cytomegalovirus infections.  167:72-77. 1993
  • Workshop on In Vitro Neutralization of Chlamydia trachomatis: Summary of Proceedings.  168:415-420. 1993
  • Evidence for a Clonal Origin of Relative Penicillin Resistance among Type 9L Pneumococci in Northwestern Canada.  165:671-675. 1992
  • Disseminated herpes zoster in the immunocompromised host: a comparative trial of acyclovir and vidarabine. The NIAID Collaborative Antiviral Study Group..  165:450-455. 1992
  • Association of Biologic False-Positive Reactions for Syphilis with Human Immunodeficiency Virus Infection.  165:1124-1126. 1992
  • Characterization of the Human IgG Antibody VLRepertoire to Haemophilus influenzae Type b Polysaccharide.  165:S53-S56. 1992
  • Disseminated Herpes Zoster in the Immunocompromised Host: A Comparative Trial of Acyclovir and Vidarabine.  165:450-455. 1992
  • Evolution of the Human Immunodeficiency Virus Epidemic among Patients Attending Sexually Transmitted Disease Clinics: A Decade of Experience.  165:541-544. 1992
  • Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals.  165:251-255. 1992
  • Infection with human t lymphotropic virus types i and ii in sexually transmitted disease clinics in Baltimore and New Orleans.  165:920-924. 1992
  • Therapeutic Approaches to Varicella-Zoster Virus Infections.  166:S51-S57. 1992
  • An experimental model of early central nervous system syphilis.  163:825-829. 1991
  • Epidemiologic studies of group 9 pneumococci in terms of protein type and 9N versus 9V capsular type.  163:812-818. 1991
  • Evaluation of a test based on baculovirus-expressed glycoprotein G for detection of herpes simplex virus type-specific antibodies.  164:1196-1199. 1991
  • Herpes simplex encephalitis: The case against brain biopsy [1].  164:426-427. 1991
  • High-level viremia in adults and children infected with human immunodeficiency virus: Relation to disease stage and cd4+lymphocyte levels.  164:72-80. 1991
  • Sexually transmitted diseases in a population of intravenous drug users: Association with seropositivity to the human immunodeficiency virus (hiv).  164:457-463. 1991
  • Use of brain biopsy for diagnostic evaluation of patients with suspected herpes simplex encephalitis: A statistical model and its clinical implications.  163:17-22. 1991
  • Use of brain biopsy for diagnostic evaluation of patients with suspected herpes simplex encephalitis: a statistical model and its clinical implications. NIAID Collaborative Antiviral Study Group..  163:17-22. 1991
  • Partial characterization of Chlamydia trachomatis isolates resistant to multiple antibiotics..  162:1309-1315. 1990
  • Bactericidal and opsonic activity of IgGl and IgG2 anticapsular antibodies to Haemophilus influenzae type b.  162:163-171. 1990
  • Behavioral contributions to acquisition of gonorrhea in patients attending an inner city sexually transmitted disease clinic.  161:938-941. 1990
  • Candida albicans in patients with the acquired immunodeficiency syndrome: Absence of a novel or hypervirulent strain.  162:513-518. 1990
  • Granulocyte-macrophage colony-stimulating factor augments human monocyte fungicidal activity for candida albicans.  161:999-1005. 1990
  • In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys Aotus trivirgatus.  162:313-321. 1990
  • Scedosporium inflatum: Clinical spectrum of a newly recognized pathogen.  161:102-107. 1990
  • Treatment of condyloma acuminatum with three different interferon-α preparations administered parenterally: A double-blind, placebocontrolled trial.  162:1270-1276. 1990
  • Determinants Of Emergence Of Antibiotic-Resistant Neisseria Gonorrhoeae.  159:900-907. 1989
  • Efficacy of Inactivated Influenza a Virus (H3N2) Vaccines Grown in Mammalian Cells or Embryonated Eggs.  160:191-198. 1989
  • Host and bacterial factors associated with haemophilus influenzae type b disease in minnesota children vaccinated with type b polysaccharide vaccine.  159:908-916. 1989
  • Syphilis and HIV Infection.  160:530-534. 1989
  • The Efficacy of Ivermectin in the Chemotherapy of Gastrointestinal Helminthiasis in Humans.  159:1151-1153. 1989
  • Primary cytomegalovirus infection in pregnancy: comparison of antibody responses to virus-encoded proteins between women with and without intrauterine infection..  158:917-924. 1988
  • Acute antibody responses to giardia lamblia are depressed in patients with aids.  157:798-804. 1988
  • Antibody response of the newborn after herpes simplex virus infection.  158:925-933. 1988
  • Antibody to herpes simplex virus (Hsv) icp-35 proteins after hsv challenge of animals immunized with hsv subunit vaccines.  157:1178-1186. 1988
  • Ceftriaxone therapy for incubating and early syphilis.  158:881-884. 1988
  • Changing patterns of herpes simplex virus infection in neonates.  158:109-116. 1988
  • Eggs of schistosoma mansoni stimulate endothelial cell proliferation in vitro.  158:556-562. 1988
  • The acquired immunodeficiency syndrome (AIDS) and infection with the human immunodeficiency virus (HIV).  158:273-285. 1988
  • Antibody Response to Herpes Simplex Virus Glycoprotein d: Effects of Acyclovir and Relation to Recurrence.  156:423-429. 1987
  • Antibody response to virus-encoded proteins after cytomegalovirus mononucleosis.  156:615-621. 1987
  • Detection of Antibodies to Herpes Simplex Virus in the Cerebrospinal Fluid of Patients with Herpes Simplex Encephalitis.  155:38-44. 1987
  • Detection of antigen to herpes simplex virus in cerebrospinal fluid from patients with herpes simplex encephalitis.  155:1172-1178. 1987
  • Estimated Prevalence of Ocular Toxoplasmosis and Toxocariasis in Alabama.  156:414. 1987
  • Naturally occurring antibodies to phosphocholine as a potential index of antibody responsiveness to polysaccharides.  155:1307-1314. 1987
  • A rabbit model of focal herpes simplex encephalitis.  153:732-735. 1986
  • Natural and vaccine-related immunity to streptococcus pneumoniae.  154:245-256. 1986
  • Antigens of treponema pallidum recognized by igg and igm antibodies during syphilis in humans.  151:264-272. 1985
  • Disproportionate expansion of a minor t cell subset in patients with lymphadenopathy syndrome and acquired immunodeficiency syndrome.  151:555-559. 1985
  • Reply.  151:971. 1985
  • The hla complex and the pathogenesis of infectious diseases.  151:1-8. 1985
  • Infections caused by herpes simplex virus in the immunocompromised host: Natural history and topical acyclovir therapy.  150:323-329. 1984
  • Vidarabine therapy for mucocutaneous herpes simplex virus infections in the immunocompromised host.  149:1-8. 1984
  • Rapid diagnosis of pneumonia due to cytomegalovirus with specific monoclonal antibodies..  147:1119-1120. 1983
  • Specific cell-mediated immunity and the natural history of congenital infection with cytomegalovirus.  148:953-961. 1983
  • Herpes simplex virus encephalitis: Laboratory evaluations and their diagnostic significance.  145:829-836. 1982
  • Cytomegalovirus infection in patients with renal transplants: Potentiation by antithymocyte globulin and an incompatible graft.  142:9-17. 1980
  • The primary role of lymphoreticular cells in the mediation of host responses to bacterial endotoxin.  141:55-63. 1980
  • Identification of patients with increased risk of infection with herpes simplex virus after renal transplantation.  140:487-492. 1979
  • Productive infection with cytomegalovirus and herpes simplex virus in renal transplant recipients: Role of source of kidney.  137:556-563. 1978
  • Treatment of infections due to Herpesvirus in humans: a critical review of the state of the art..  133 Suppl:A101-A108. 1976
  • Adenine Arabinoside for Therapy of Herpes Zoster in Immunosuppressed Patients: Preliminary Results of a Collaborative Study.  133:A184-A191. 1976
  • Effect of adenine arabinoside on cytomegalovirus infections.  130:32-39. 1974
  • Effect of adenine arabinoside on severe herpesvirus hominis infections in man.  128:658-663. 1973
  • Inhibition of growth of candida albicans by iron-unsaturated lactoferrin: Relation to host-defense mechanisms in chronic mucocutaneous candidiasis.  124:539-544. 1971
  • International Standard Serial Number (issn)

  • 0022-1899
  • Electronic International Standard Serial Number (eissn)

  • 1537-6613